文献速递泌尿生殖与妇科肿瘤放疗

两分次高剂量率近距离放疗单药治疗前列腺癌的疗效与毒性

Effectiveness, toxicity and impact on quality of life of high-dose-rate brachytherapy delivered in two fractions as monotherapy in patients with prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-01-17

这项回顾性单中心队列研究纳入2005至2021年接受28 Gy(14 Gy×2)高剂量率近距离放疗单药治疗的175例前列腺癌患者,94%为低危或中危。低危和中危患者五年累积生化复发率分别为3.0%和9.6%,12个月时3%发生3级泌尿毒性、无3级肠道毒性。作者认为该方案在生化复发方面似乎安全,严重泌尿和肠道毒性比例低。

要点

  • 低危患者五年累积生化复发率为3.0%(95%CI 0%-13.3%)。
  • 中危患者五年累积生化复发率为9.6%(95%CI 4.7%-16.7%)。
  • 12个月时3%发生3级泌尿毒性,无3级肠道毒性。

核心结论

  • 作者认为,在主要为低危和中危的前列腺癌患者中,两分次高剂量率近距离放疗单药治疗在生化复发方面似乎安全,严重泌尿和肠道毒性比例低。

研究设计与样本

  • 回顾性单中心队列研究,纳入2005至2021年在本机构接受28 Gy高剂量率近距离放疗(14 Gy×2分次)单药治疗的连续前列腺癌患者,共175例,中位年龄68岁(范围51-80),中位随访60个月(范围0-174)。
  • 94%的患者被归类为低危或中危。

主要发现

  • 低危患者估计五年累积生化复发率为3.0%(95%CI 0%-13.3%),中危患者为9.6%(95%CI 4.7%-16.7%)。
  • 诊断时PSA超过10 ng/mL是生化复发的显著危险因素(OR=3.29,95%CI 1.01-10.67)。
  • PSA最低值≤0.1 ng/ml是显著的正面预后因素,与较低的生化复发风险相关(OR=0.11,95%CI 0.03-0.33)。
  • 12个月时,22%的患者发生2级泌尿毒性、3%发生3级泌尿毒性;2%的患者发生2级肠道毒性、无3级肠道毒性。
  • 12个月时,治疗前至少有一定勃起功能的患者中49%出现功能受损。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this retrospective, single-center cohort study was to evaluate the effectiveness and safety of two-fraction high-dose-rate brachytherapy (HDR-BT) as monotherapy in a consecutive cohort of prostate cancer patients. METHODS: We included consecutive patients who received 28 Gy HDR-BT in two fractions (14 Gy × 2) as monotherapy during 2005 to 2021 at our institution. Eligible patients were derived from an institutional database consisting of prospectively collected data. Primary endpoint was biochemical recurrence (BCR) and secondary endpoints included toxicity (assessed through both healthcare provider and patient-reported outcomes) and quality-of-life (QoL) assessment. RESULTS: In total, 175 patients with prostate cancer (94 % classified as low- or intermediate-risk) were treated with HDR-BT during the study period with a median age of 68 years (range: 51-80), and a median follow-up of 60 months (range: 0-174). The estimated five-year cumulative BCR rate was 3.0 % (95 % Confidence Interval (CI): 0 %-13.3 %) for low-risk patients and 9.6 % (95 % CI: 4.7 %-16.7 %) for intermediate-risk patients. PSA exceeding 10 ng/mL at diagnosis was a significant risk factor for BCR (Odds Ratio (OR) = 3.29, 95 % CI: 1.01-10.67) whereas PSA of ≤0.1 ng/ml as nadir was a significant positive prognostic factor, associated with lower risk of BCR (OR = 0.11, 95 % CI: 0.03-0.33). At 12 months, 22 % of the patients had grade 2 and 3 % grade 3 urinary toxicity whereas 2 % of patients had grade 2 and none grade 3 bowel toxicity. At 12 months, 49 % of the patients with at least some erectile function before the treatment, had an impaired function. CONCLUSION: We found that two-fraction HDR-BT as monotherapy among patients with mainly low- and intermediate-risk prostate cancer appears to be safe in terms of biochemical recurrence, with a low proportion of severe urinary and bowel toxicity.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Staby Olsén J, Valachis A, Johansson B, et al. Effectiveness, toxicity and impact on quality of life of high-dose-rate brachytherapy delivered in two fractions as monotherapy in patients with prostate cancer. Clin Transl Radiat Oncol. 2025. PMID: 39901942. doi:10.1016/j.ctro.2025.100923

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。